Key Insights

Highlights

Success Rate

79% trial completion

Published Results

310 trials with published results (15%)

Research Maturity

920 completed trials (44% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.7%

242 terminated out of 2068 trials

Success Rate

79.2%

-7.4% vs benchmark

Late-Stage Pipeline

8%

170 trials in Phase 3/4

Results Transparency

34%

310 of 920 completed with results

Key Signals

310 with results79% success242 terminated

Data Visualizations

Phase Distribution

1,645Total
Not Applicable (280)
Early P 1 (26)
P 1 (620)
P 2 (549)
P 3 (150)
P 4 (20)

Trial Status

Completed920
Recruiting350
Unknown270
Terminated242
Active Not Recruiting120
Not Yet Recruiting88

Trial Success Rate

79.2%

Benchmark: 86.6%

Based on 920 completed trials

Clinical Trials (2068)

Showing 20 of 20 trials
NCT07760012Not ApplicableRecruiting

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

NCT07546500Phase 3RecruitingPrimary

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07761416Early Phase 1Not Yet RecruitingPrimary

Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention

NCT05601752Phase 2Active Not RecruitingPrimary

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT06851429RecruitingPrimary

Ovarian Cancer Identification on CT Using Deep Learning

NCT05123482Phase 1Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT04044859Phase 1Active Not Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT06840886Phase 1Recruiting

A Study of PHST001 in Advanced Solid Tumors

NCT06787612Phase 2RecruitingPrimary

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT04354246Phase 1Completed

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT02884648Phase 2Active Not Recruiting

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

NCT06242470Phase 1Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06792435Phase 1Active Not Recruiting

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

NCT07736937Phase 1RecruitingPrimary

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

NCT07757711Not Yet RecruitingPrimary

Implementation of New Models of Ovarian Carcinoma Resistant to Therapy

NCT07755436Phase 1RecruitingPrimary

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

NCT07743164Phase 3Not Yet RecruitingPrimary

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

NCT04585750Phase 1Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT06824467Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT03762733Enrolling By Invitation

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

Scroll to load more

Research Network

Activity Timeline